Clinical Trial Update: NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating NY-ESO-1-redirected T cells in patients with advanced melanoma and sarcoma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Sarcoma

Drugs mentioned

• NY-ESO-1-redirected T Cells

Snippet

Sponsor: Centre Hospitalier Universitaire Vaudois | Conditions: Advanced Melanoma, Melanoma Metastatic | Phase 1 | Status: RECRUITING